dnpm:DIP - digital platform of the German Network for Personalized Medicine
- Conditions
- Patients with severe, advanced cancer who have undergone guideline-based therapy and patients with rare tumors for which no guideline-based therapy exists are admitted.
- Registration Number
- DRKS00033869
- Lead Sponsor
- Zentrum für Personalisierte Medizin, Universitätsklinikum Tübingen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
1. the patient has a defined oncological disease/clear access diagnosis
2. the patient should be referred after presentation to an organ-specific tumor board (internal/external) of a tumor center or oncological focus.
3. physical and mental condition and life expectancy justify continued treatment. The patient is clinically qualified for molecular-based therapy.
4. the guideline-compliant therapies have been completed in the foreseeable future.
5. rare and aggressive oncological diseases can be presented earlier.
6. further diagnostics are aimed at therapeutic intervention.
7. capacity to consent
8. documented patient consent
Exclusion Criteria
1. lack of capacity to consent
2. nonage
3. lack of declaration of consent
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The aim of the project is to establish a registry for the standardized collection and documentation of long-term data of all patients who are discussed in a MTB of the DNPM in the context of clinical care. Among other things, the dnpm:DIP should support patient care in the context of personalized medicine through a more efficient interdisciplinary flow of information in the long term.
- Secondary Outcome Measures
Name Time Method - Ensuring quality in the prospective documentation of MTB cases with a focus on clinical outcome parameters such as progression-free survival (PFS), PFS ratio, modified PFS ratio, overall survival (OS) and other response assessments (e.g. imaging, therapy resistance)<br>- Follow-up of the implementation of the therapy recommendations made in the MTB<br>- Provision of the collected care data for long-term research/development of new hypotheses and therapeutic approaches<br>- Quality assurance and research into treatment in personalized medicine